[Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine].
In a controlled randomized cross-over trial, 21 patients with coronary artery disease and frequent ventricular arrhythmias were studied to test the efficacy and tolerance of mexiletine 200 mg t.i.d. in comparison to a released application form of mexiletine perlongettes 360 mg b.i.d. During 24-hour Holter monitoring, all patients but one showed more than 30 ventricular premature beats/h; additionally, in 16 patients, complex ventricular arrhythmias (Lown class IV) were documented. In all patients each medication was given for 5 days. Before treatment and during both medication periods, a 4 days' wash-out period was interposed. Mexiletine and mexiletine perlongettes each resulted in a suppression of ventricular ectopy of more than 84% in 10/21 patients (47%); in two patients the response was different. The mean reduction rate in all patients was 68% for mexiletine and 64% for mexiletine perlongettes. In the responder group, the mean reduction rate amounted to 95% under both medications. Ventricular pairs and tachycardia were reduced by more than 90%. Plasma concentration under mexiletine perlongettes was slightly higher, as compared to the standard form of mexiletine; however, under mexiletine, significant changes of plasma concentration were observed during the day only when the standard form was used. Side effects were observed in 8/21 patients (38% for mexiletine) and in 5/21 patients (24% for mexiletine perlongettes). These were mainly gastrointestinal or neurological, but were mild in all patients and did not necessitate discontinuation of the medication in any patient.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000188:drug therapy
D003692:Delayed-Action Preparations; D008801:Mexiletine
Antiarrhythmische Wirksamkeit und Verträglichkeit von retardiertem im Vergleich zu unretardiertem Mexiletin.